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ABSTRACT
Introduction Fungal infections of the cornea, fungal 
keratitis (FK), are challenging to treat. Current topical 
antifungals are not always effective and are often 
unavailable, particularly in low- income and middle- income 
countries where most cases occur. Topical natamycin 5% 
is usually first- line treatment, however, even when treated 
intensively, infections may progress to perforation of the 
eye in around a quarter of cases. Alternative antifungal 
medications are needed to treat this blinding disease.
Chlorhexidine is an antiseptic agent with antibacterial 
and antifungal properties. Previous pilot studies suggest 
that topical chlorhexidine 0.2% compares favourably with 
topical natamycin. Full- scale randomised controlled trials 
(RCTs) of topical chlorhexidine 0.2% are warranted to 
answer this question definitively.
Methods and analysis We will test the hypothesis 
that topical chlorhexidine 0.2% is non- inferior to topical 
natamycin 5% in a two- arm, single- masked RCT. 
Participants are adults with FK presenting to a tertiary 
ophthalmic hospital in Nepal. Baseline assessment 
includes history, examination, photography, in vivo 
confocal microscopy and cornea scrapes for microbiology. 
Participants will be randomised to alternative topical 
antifungal treatments (topical chlorhexidine 0.2% and 
topical natamycin 5%; 1:1 ratio, 2–6 random block size). 
Patients are reviewed at day 2, day 7 (with reculture), day 
14, day 21, month 2 and month 3. The primary outcome 
is the best spectacle corrected visual acuity (BSCVA) at 
3 months. Primary analysis (intention to treat) will be by 
linear regression, with treatment arm and baseline BSCVA 
prespecified covariates. Secondary outcomes include 
epithelial healing time, scar/infiltrate size, ulcer depth, 
hypopyon size, perforation and/or therapeutic penetrating 
keratoplasty (corneal transplant), positive reculture rate 
(day 7) and quality of life (EuroQol-5 dimensions, WHO/
PBD- VF20, WHOQOL- BREF).
Ethics and dissemination The Nepal Health Research 
Council, the Nepal Department of Drug Administration 
and the London School of Hygiene and Tropical Medicine 
ethics committee have approved the trial. The results 
will be presented at local and international meetings and 
submitted to peer- reviewed journals for publication.
Trial registration number ISRCTN14332621; pre- results.
INTRODUCTION
Fungal keratitis (FK) is a severe and potentially 
blinding corneal infection (figure 1).1 2 The 
burden is greatest in tropical and subtropical 
countries, probably due to a combination of 
climate (higher temperatures and humidity) 
and frequent agriculture- related eye inju-
ries.3 It is one of the causes of microbial kera-
titis (MK) and accounts for between 20% 
and 60% of corneal infections diagnosed in 
Strengths and limitations of this study
 ► First large- scale randomised controlled clinical trial 
comparing chlorhexidine 0.2% to natamycin 5% for 
the treatment of fungal keratitis.
 ► This study benefits from a pragmatic design: as a 
non- inferiority trial, if chlorhexidine is found to be 
within a predefined non- inferiority margin of 0.15 
logMAR of natamycin at 3 months a recommenda-
tion to use chlorhexidine 0.2% can be made; this is a 
far cheaper, easy to formulate medication that could 
significantly increase access to antifungal treatment 
for the target population.
 ► Clinicians are masked to the treatment allocation, 
however, due to different physical appearance it 
is not possible to mask patients to their allocated 
treatment.
 ► This study will also assess the superiority of either 
medication as well as a number of key secondary 
outcome measures, analysed by arm.
 ► First randomised controlled trial investigating fungal 
keratitis to use in vivo confocal microscopy as a di-
agnostic tool for the detection of fungal elements.
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tropical regions.4 It is often inadequately treated with 
significant barriers to receiving appropriate, timely 
intervention, compounded by indiscriminate and inap-
propriate use of conventional medicines such as topical 
corticosteroids or harmful traditional eye medicines.1 2 5 
Furthermore, when appropriate treatment is available, 
up to 30% of patients receiving current ‘gold- standard’ 
therapy progress to corneal perforation and/or eye- loss 
(figure 2).1 6 7
Treatment for FK almost always involves topical anti-
fungal agents. Surgical intervention, usually in the form 
of therapeutic penetrating keratoplasty (TPK), is gener-
ally reserved for cases of corneal perforation or progres-
sive infection refractory to medical therapy. Corneal 
transplantation is also performed for visual rehabilitation 
after the acute infection has resolved. There are a limited 
number of antifungals available for treating FK, which 
fall into four main groups: imidazoles, triazoles, polyenes 
and fluorinated pyrimidines. These may be available 
topically, orally or by intravenous injection. Subconjunc-
tival, corneal stromal or intracameral injections may also 
be given. The treatment of yeasts (Candida spp) is often 
different to filamentous fungi, with the former being 
more common in temperate climates and the latter in hot 
and humid locations.8 9
There have been several clinical trials comparing treat-
ment options for FK, which have been systematically 
reviewed.10 11 Natamycin (NATA), which was approved 
in the 1960s by the U.S. Food and Drug Administra-
tion (FDA) for FK, has been compared with a number 
of newer agents, including voriconazole. Natamycin and 
voriconazole have been compared in four trials, with the 
meta- analysis favouring natamycin.6 10 12–14
As a result, first line management of filamentous FK is 
usually with topical natamycin 5% when this is available. 
This was added to the WHO Essential Medicines List in 
2017 for this indication. However, even when inten-
sive topical natamycin is initiated, infections frequently 
progress relentlessly to perforation and loss of the eye in 
about a quarter of cases, figure 2.1 6 7 Moreover, in many 
countries, antifungal eye- drop treatments are simply not 
available. This includes most countries in sub- Saharan 
Africa, some Asian countries and some countries in 
Europe.1 2 Natamycin is relatively expensive even if it is 
available. Therefore, additional alternative and more 
affordable drugs are clearly needed if the outcome of 
these infections is to improve.
Chlorhexidine (CHX) is an antiseptic agent, with both 
antibacterial and antifungal properties. It is a widely used 
broad- spectrum biocide, killing micro- organisms through 
cell membrane disruption.15–17 CHX has been used in 
ophthalmology for over 30 years as an eye- drop preser-
vative and for sterilising contact lenses, and has also 
been used to treat Acanthamoeba and FK.9 18–22 In a study 
of potential antifungal treatments, CHX was effective 
both in vitro against FK isolates from India and Ghana, 
as well as in an Indian case series.23 Subsequently, two 
pilot randomised controlled trials (RCTs) of CHX for FK 
were conducted. In the first, three CHX concentrations 
(0.05%, 0.1%, 0.2%) were compared with each other 
Figure 1 Fungal keratitis and corneal scarring. (A) Active fungal keratitis with signs of acute inflammation and corneal 
ulceration. Photograph taken at presentation to SCEH. (B) Corneal scar, the blinding sequela of a resolved episode of fungal 
keratitis. Photograph taken at 2 months following presentation (same patient as (A)). SCEH, Sagarmatha Choudhary Eye 
Hospital.
Figure 2 Progressive fungal keratitis. (A) Early filamentous fungal keratitis; started immediately on intensive topical antifungal 
treatment (Natamycin 5%). (B) The same case 1 week later, unresponsive to intense natamycin 5% treatment, with progression 
of the infection.
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and natamycin 5%; this concluded CHX 0.2% had reli-
able antifungal action.19 The same concentration is used 
in mouthwash to prevent oral candidiasis. In the second 
trial, CHX 0.2% was compared with topical natamycin 
2.5% (half standard concentration). There was evidence 
CHX produced a more favourable response by 5 days (RR 
0.23, 95% CI 0.09 to 0.63).18 A systematic review found 
a trend favouring CHX over natamycin in ‘curing’ by 
21 days (RR 0.70, 95% CI 0.45 to 1.09), suggesting CHX 
might prove superior in adequately powered trials.10 CHX 
is safe and well tolerated at these concentrations.18 19 22 24 
Based on this, CHX is used for treating FK in several coun-
tries.1 9 11 However, the combined size of these two pilot 
trials comparing CHX and natamycin is not sufficient to 
reach firm conclusions. Currently, the meta- analysis indi-
cates equipoise in terms of which treatment is the best for 
treating FK.
Objectives
The primary objective of this study is to determine if 
topical CHX 0.2% is non- inferior to topical natamycin 
5% for treating filamentous FK, in terms of vision at 
3 months. The secondary objectives are: (1) to determine 
whether either treatment (CHX 0.2% or natamycin 5%) 
is superior to the other, in terms of vision at 3 months and 
(2) to determine whether there is a difference between 
CHX 0.2% and natamycin 5% in terms of secondary clin-
ical outcomes including infiltrate/scar size, time to re- ep-
ithelialisation, reculture rates at 1 week and the effect 
of the alternative treatments on the Quality of Life of 
participants.
CHX is cheap, stable and easily prepared by aqueous 
dilution. If CHX is found to be non- inferior (or even supe-
rior) to natamycin this offers the potential of an effec-
tive, affordable and accessible treatment for FK, which 
could benefit millions of people each year who currently 
have no treatment options. This trial is a response to this 
expressed need from both clinicians and patients for a 
readily available and affordable medication for fungal 
infection.
METHODS AND ANALYSIS
Trial design
We are conducting a single- masked, non- inferiority RCT 
comparing CHX 0.2% to natamycin 5% for the treatment 
of FK. The non- inferiority design of this trial offers a 
clinically pragmatic way to address this important ques-
tion: if CHX is found to be within the prespecified non- 
inferiority margin of 0.15 logMAR (about 1.5 Snellen 
lines) then CHX may prove to be a sustainable solution 
for this aspect of the complex problem of FK.
Trial summary
This RCT follows a two- stage recruitment process 
(figure 3). All patients presenting with acute MK are 
reviewed and enrolled into stage 1, following written, 
informed consent. This involves history, examination 
and investigations (corneal scrapes for microbiological 
assessment and in vivo confocal microscopy (IVCM)). If 
there is evidence of fungal hyphae on smear or confocal 
microscopy, patients then proceed to stage 2. A trial eligi-
bility checklist is completed and stage 2 written informed 
consent is conducted. We will recruit 500 patients into 
Figure 3 Overview of the clinical trial. Microbial keratitis is 
defined as presence of corneal epithelial ulceration (>1 mm 
in diameter), corneal stromal infiltrate and signs of acute 
inflammation (eg, conjunctival injection, anterior chamber 
inflammatory cells, hypopyon). Fungal elements to be 
detected by smear microscopy and/or confocal microscopy. 
Those eligible will be randomised 1:1 to CHX or NatA 
(n=500). BSCVA, best spectacle corrected visual acuity; CHX, 
chlorhexidine; TPK, therapeutic penetrating keratoplasty.
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stage 2. Eligible FK patients are then randomised 1:1 to 
receive either natamycin 5% or CHX 0.2% topical treat-
ments hourly for the first week, then 2 hourly for the 
subsequent 2 weeks. Ongoing treatment duration will 
then be tailored to clinical response. Study personnel are 
masked to the treatment allocation. Patients are usually 
initially admitted and followed up on day 2, day 7 (with 
reculture), day 14, day 21, month 2 and month 3. The 
primary outcome is the best spectacle corrected visual 
acuity (BSCVA) at 3 months.
Trial setting
Low- land Nepal, a region with a high burden of FK, 
provides a suitable location to conduct a clinical trial 
that requires a relatively large sample size. This trial will 
be conducted in Sagarmatha Choudhary Eye Hospital 
(SCEH), Lahan, Siraha District in south eastern Nepal. 
SCEH treats approximately 800 cases of keratitis per 
month, half of which is attributable to fungal infection.1 25 
SCEH is a tertiary- level ophthalmic hospital, with several 
satellite Eye Care Clinics (ECCs) that refer patients to 
SCEH directly as required. SCEH and its ECCs serve an 
estimated population of about 5 million people. Due to 
its proximity to the border, approximately 50% of the 
outpatients are Indian nationals. It is anticipated that 
the study participants will present to the hospital from 
multiple districts within the region. Potentially eligible 
individuals will be recruited from outpatient clinics or 
referred directly by the ECCs to the study team. Based on 
the numbers of patients attending, it should be possible 
to complete recruitment of 500 participants within 6–12 
months. A second separate trial in East Africa (Tanzania 
and Uganda) will also be conducted to compare CHX 
0.2% to natamycin 5% following a very similar protocol to 
the one described here. This will be registered as a sepa-
rate trial. This will enable us to assess the generalisability 
of the findings in two geographically distinct regions with 
potentially different fungal aetiologies and susceptibility 
patterns.
Eligibility criteria
Potential participants need to meet all the inclusion 
criteria and have none of the exclusion criteria listed 
in table 1. In summary, they need to have an active FK 
defined as acute MK characterised by corneal epithelial 
ulceration (>1 mm in diameter), corneal stromal infiltrate 
and signs of acute inflammation (eg, conjunctival injec-
tion, anterior chamber inflammatory cells, hypopyon) 
in conjunction with evidence of a filamentous fungal 
infection on smear microscopy and/or IVCM. There is 
strong evidence supporting the use of IVCM for diag-
nosing filamentary FK. Studies have reported sensitivities 
of 85.7%–89.2% and specificities of between 81.4% and 
92.7%, respectively.26–28 As some patients will be enrolled 
on the basis of the results of IVCM which is unable to 
detect most bacteria reliably, some patients with micro-
scopically confirmed fungal infection will subsequently 
also be found to have had mixed infection at the time 
of being recruited into the study, as bacterial cultures 
may become positive a few days after enrolment. Based 
on previous experience at SCEH this is likely to account 
for about 10% of cases. These patients are included in 
the study but excluded from the primary analysis of the 
primary outcome (see below). Secondary analyses will 
include mixed infections.
Consent procedures
There are two independent consent stages in this trial: 
stage 1, where all adult patients with MK are eligible; 
and stage 2, only for FK patients meeting the eligibility 
criteria. The two- stage process enables data collection on 
all potential patients at baseline before a diagnosis of FK is 
confirmed. All patients who are eligible to participate will 
be given a participant information sheet in Nepali and its 
contents read to them. There will be an opportunity to 
discuss any questions that they might have. If the patient 
would like to participate, they will be asked to read and 
sign or place a thumb print on the study consent form. 
The consent will be witnessed by the eye health worker, 
confirmed by a signature on the form. For patients who 
are unable to read the documentation a second witness 
who is unrelated to the study is required. Consent forms 
are given in online supplementary appendix 1.
Baseline assessment
The detailed baseline assessment is described in table 2. 
This includes clinical examination, corneal photography, 
IVCM and the collection of microbiology samples. Quality 
of life questionnaires will also be completed (EuroQol-5 
dimensions (EQ- 5D), World Health Organization Preven-
tion of Blindness and Deafness 20- item Visual Functioning 
Questionnaire (WHO/PBD- VF20), World Health Organi-
zation Quality of Life: Brief Version (WHOQOL- BREF), 
details of the scoring for these are given in table 2.
Randomisation and masking
Sequence generation
A computer- generated randomisation list will be prepared 
by an independent statistician at London School of 
Hygiene and Tropical Medicine (LSHTM), who will hold 
the sequence, will not be masked, and will not be involved 
in any other aspect of the trial. The sequence is in a 1:1 
allocation ratio of CHX to NATA, with a random block 
size (2, 4 or 6).
Allocation concealment and implementation
The randomisation sequences will be concealed in 
sequentially numbered, opaque envelopes. The enve-
lopes will be prepared by a person independent of all 
other aspects of the trial. The randomisation adminis-
trator (nurse or pharmacist) will conduct the random 
allocation procedure. The investigational products will 
be stored in the trial coordination office in a locked and 
separate drug cabinet dedicated for this clinical trial only. 
The cabinet will only be used for drug storage and will 
only be accessed by the randomisation administrator. The 
randomisation administrator will work in a separate room 
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in the clinic. After the patient has been recruited and 
assessed, they will be guided to this separate room where 
the randomisation allocation will be conducted.
Masking
The topical treatments being compared in this trial have a 
different appearance: the CHX 0.2% is a clear, colourless 
solution and the natamycin 5% is an opaque, white suspen-
sion. Therefore, it is not possible to mask the participants 
to this difference in visual appearance. However, the 
patients will not be told which treatment they have been 
allocated. Prior to any follow- up clinical examinations, a 
nurse, otherwise uninvolved in the study, will wipe away 
any white natamycin residue from the patient’s eyes to 
avoid unmasking the clinical assessor. This procedure was 
used successfully in other trials.6 All clinicians involved 
in the clinical assessment of the patients will be masked 
to the allocation. The statistician who will perform the 
primary analysis will be masked to the allocation and only 
receive the actual allocation code sequence from the 
independent statistician after the analysis code has been 
prepared and pre- tested with a test sequence. The primary 
outcome is visual acuity at 3 months assessed by an optom-
etrist who will not have been involved in any other aspects 
of the trial and masked to the allocation. By 3 months, the 
treatment courses are likely to be completed. There will 
be masked grading of the photographs to independently 
confirm outcome measures and assess for any systematic 
bias on the part of the clinical examiners.
Unmasking
Unmasking is a serious action and should only be 
performed if necessary to ensure the safety of a study 
participant. Anyone unmasked to randomised treatment 
Table 1 Inclusion and exclusion criteria for enrolment in stage 1 (MK cases) and stage 2 (the randomised controlled trial)
Inclusion criteria (all must be met) Exclusion criteria (any of the following)
Stage 1
1. Acute MK characterised by: 1. Patients aged less than 18 years
 ► Corneal epithelial ulceration >1 mm diameter 2. Patients unable or unwilling to provide informed consent
 ► Corneal stromal infiltrate 3. Patients who do not have acute MK or where there is a more 
likely alternative diagnosis
 ► Acute inflammation: for example, conjunctival injection, 
anterior chamber inflammatory cells, hypopyon
  
2. Adults (18 years and older)   
3. Able to provide informed consent   
Stage 2
1. Acute MK characterised by: 1. Unwilling/unable to participate in trial and/or attend follow- 
up
 ► Corneal epithelial ulceration >1 mm diameter 2. Aged less than 18 years
 ► Corneal stromal infiltrate 3. Pregnancy: self- reported, or by urine pregnancy test if 
uncertain.
 ► Acute inflammation: for example, conjunctival injection, 
anterior chamber inflammatory cells, hypopyon
4. Breast feeding: self- reported
2. Filamentous fungal hyphae visualised on smear microscopy 
and/or IVCM
5. Prior topical antifungal treatment
3. Agree to be randomised to either treatment arm and are 
able to give informed consent
6. No light perception in the affected eye
4. Agree to be followed up at 2 days, 1 week, 2 weeks, 3 
weeks, 2 months and 3 months
7. Fellow eye visual acuity <6/60
5. Adults (18 years and older) 8. Acanthamoebic infection visualised by smear microscopy or 
IVCM
  9. Clinical evidence of herpetic keratitis
  10. Known allergy to study medication (including preservatives)
  11. Previous keratoplasty in the affected eye
  12. Bilateral corneal ulcers
  13. Very severe ulcers warranting immediate evisceration or 
conjunctival flap
14. Endophthalmitis
IVCM, in vivo confocal microscopy; MK, microbial keratitis.
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Table 2 Baseline assessment
Assessment Details
Visual acuity Presenting, Pin- Hole and best spectacle corrected visual acuity) will be measured using an ETDRS Tumbling- E 
logMAR 3 m chart (Good- Lite Inc, USA) mounted on an ESC 2000 ETDRS LED Cabinet, (Good- Lite Inc, USA) 
by a trial- certified optometrist, for each eye separately
Contrast 
sensitivity
Measured using the Peek Contrast Sensitivity smartphone application running on Android OS with a Sony 
Xperia Z3 Compact smartphone (Sony, Japan).26
Clinical 
photographs
Photographs will be taken separately of both corneas using a Nikon D7500 camera with an AF- S Micro Nikkor 
105 mm lens and lens mounted SB-200 flash units (Nikon, Japan). A standardised photography protocol is 
used to ensure images can be compared between time points. Standardised magnification will be used to 
allow epithelial defect and stromal infiltrate size measurements to be made.
Slit- lamp 
examination
Both eyes will be examined using a slit- lamp biomicroscope (standard ophthalmology examination) to assess 
the anterior segment of the eye. This examination will be performed by an ophthalmic clinician experienced in 
managing MK. Particular attention will be paid to the following features:
1. Eyelids: trichiasis, lagophthalmos, facial weakness, Bell’s reflex
2. Suppuration
3. Conjunctival inflammation
4. Corneal sensation
5. Cornea epithelial defect (measuring the longest dimension and the longest perpendicular) and ulcer depth
6. Corneal inflammatory infiltrate depth, size, profile, colour, edge pattern, texture, satellites
7. Anterior chamber inflammatory cells, hypopyon, endothelial plaque
8. Relative afferent pupillary defect
In vivo 
confocal 
microscopy 
(IVCM)
The Heidelberg Retinal Tomograph 3 IVCM enables the clinician to examine the cornea down to the cellular 
level. It is able to detect the presence of fungal hyphae.27 28 A sterile, single- use disposable cap covers the 
objective lens and is changed between patients. Volume scans will be performed which provide a series of 
400×400 µm images over a depth range of 80 µm. The resolution of the corneal scanning module is 7.6 µm. 
IVCM images will be collected in a systematic way, starting at the centre of the ulcer, then at the superior, 
inferior, nasal and temporal borders of the ulcer. Volume scans will be performed in all of these locations, 
starting at the level of the corneal epithelium, and ending at the deepest affected aspect of the cornea 
assessed from IVCM images. Images will be assessed during the examination.
Ocular sample 
collection
The following samples will be collected from the corneal ulcer of each patient at the baseline assessment:
1. Corneal scrape specimens for microscopy and microbiological culture. A corneal scrape will be collected 
from the corneal ulcer after application of preservative free proxymetacaine local anaesthetic eye- drops 
(Minims). Sterile needles are used to take corneal scrape specimens and then place on to glass slides for 
immediate Gram stain, KOH and Calcofluor white. Samples will be directly inoculated onto blood, chocolate, 
Sabouraud agar and broths for culture.
2. Corneal specimen collection for PCR. Two sterile swabs will be gently swept over the surface of the corneal 
ulcer and placed into a 2 mL tube. The swabs will be for pathogen detection by PCR, fungal sequencing and 
assessment of point of care tests for fungal infections. Swabs will be stored dry at −80°C. If swab yields are 
found to be too low for analysis an additional corneal scrape will be collected for PCR. The analysis of the 
PCR samples will not form part of the RCT workup and report.
HIV testing All individuals presenting with MK would be offered counselling and testing services. If this is found to be 
positive and the patient is unknown to the HIV care services an appropriate referral will be made. HIV testing is 
performed using HIV Tri- Dot rapid diagnostic test (J. Mitra & Co, India)
Random blood 
glucose
There is a suggestion that individuals with diabetes may be more susceptible to FK. Participants will be 
offered a random blood glucose test, on a finger prick sample, analysed using HumaLyzer Primus (HUMAN 
Gesellschaft für Biochemica und Diagnostica mbH, Germany). If this is above 6.1 mmol/L they will be referred 
to the hospital physicians for assessment and formal diagnosis of impaired glucose tolerance or diabetes 
mellitus. This level is considered a suitable cut- off to detect individuals with diabetes and has been validated 
in a south- Asian population.34
Continued
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for the purpose of creating analyses for independent data 
and safety monitoring committees will not be involved in 
any other aspects of the conduct or final analysis of the 
study. A list will be maintained of all unmasked members 
of staff and will be approved by the chief investigator. 
Such staff members must sign a document to indicate 
that they are aware of their responsibilities with respect 
to confidentiality. The processes used to provide access to 
unmasked treatment codes and reports relating to these 
codes shall be documented.
Intervention and treatment
The standard of care in this hospital is for cases of FK 
to be admitted. If willing, patients will be admitted for 
close observation and supervised treatment, until there 
are signs of improvement and the supervising clinician 
considers it safe to provide ongoing management on an 
outpatient basis.
Trial treatment arms
1. CHX 0.2% w/v eye- drops
CHX 0.2% w/v solution, as eye- drops, will be applied 
to the surface of the infected eye (one drop per appli-
cation). The CHX 0.2% w/v eye- drops used in these 
studies is produced by Mandeville Medicines, UK.
2. Natamycin 5% eye- drops
Natamycin 5% w/v suspension, as eye- drops, will be 
applied to the surface of the infected eye (one drop 
per application). Topical natamycin 5% is produced by 
FDC Pharmaceuticals, India.
Dosing schedule
Both trial treatment arms will follow the same dosing 
schedule. Eye- drops will be given hourly day and night 
for 48 hours, then hourly while awake for 5 days, and then 
2 hourly while awake for two further weeks. If the ulcer 
has healed (epithelial defect less than 1 mm, infiltrate 
resolved, with or without corneal scarring), then treat-
ment is stopped. If resolving stromal infiltration and/or 
epithelial defect >1 mm but <5 mm, treatment is reduced 
to four times daily. If resolving but with epithelial defect 
>5 mm and/or stromal infiltration/hypopyon, treatment 
is reduced to six times daily. Treatment duration will be 
tailored to clinical response, with patients reviewed regu-
larly while on treatment in addition to their scheduled 
study visits.
Topical treatments
Several other topical medicines are used in the standard 
care of people with corneal infections:
1. Fluorescein sodium ophthalmic strips (Contacare 
Ophthalmics and Diagnostics, India) to highlight the 
area of cornea epithelial defect.
2. Anaesthetic eye- drops to anaesthetise the cornea 
before procedures such as microbiology samples: 
Assessment Details
Quality of life 
questionnaires
For those with confirmed FK and who are enrolled in the trial, there will be several additional baseline 
assessments to evaluate the impact of FK on quality of life.
Vision- related quality of life (VRQoL): will be assessed by a vision disease specific tool the WHO/PBD- 
VF20.35 This tool measures the impact of visual impairment in the person’s life including mental well- being, 
dependency and social functioning. These have been used in a number of other vision related studies to 
show a difference in QoL.36 37 This instrument consists of 20 questions divided into three sub- scales: visual 
symptom, general functioning and psychosocial. It begins by asking the patient ‘Overall, how would you 
rate your eyesight using both eyes?’; and uses a five point scale answer option such as ‘very good’, ‘good’, 
‘moderate’, ‘bad’, ‘very bad’. The test is scored out of 100, with higher scores reflecting a better VRQoL.
General health- related quality of life: We will use the EQ- 5D questionnaire and EQ- Visual Analogue Scale. 
The EQ- 5D is a standardised tool to measure health outcomes.38 Patients will also be assessed using the 
WHOQOL- BREF.39 This has good applicability in low and middle- income countries as it was developed 
simultaneously from concept across 18 countries in Africa, Asia and Latin America. It measures 4 domains 
of health: Physical Health, Psychological Health, Social Relationships, and Environment. It asks respondents 
26 questions how much (frequency) they have experienced and/or were able to do things (eg, feel safe, able 
to concentrate, enjoy life) in the past 4 weeks and how satisfied they are with certain aspects of their lives 
(eg, sleep, capacity for work). Each question is scored between one and five in a positive direction, with one 
being attributed for a very low or dissatisfied quality of life, and five being very good or very satisfied with their 
quality of life (ie, higher scores denote a higher quality of life). Each domain has its own score calculated by 
calculating the mean of the item scores within each domain. In addition, there are two items that are examined 
separately: question 1 asks about an individual’s overall perception of quality of life and question 2 asks about 
an individual’s overall perception of their health. These are scored on the same positive scale from one to five. 
The mean domain scores can then be multiplied by four in order to make domain scores comparable with the 
scores used in the WHOQOL-100.39
Assessment performed at baseline with details of how they are made.
AF- S, Autofocus Single; EQ- 5D, EuroQol-5 dimensions; ETDRS, Early Treatment Diabetic Retinopathy Study; FK, fungal keratitis; KOH, 
Potassium Hydroxide; MK, microbial keratitis; RCT, randomised controlled trial.
Table 2 Continued
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Proxymetacaine 0.5% eye- drop Minims (Bausch and 
Lomb, UK).
3. Antibiotic eye- drops may be used as per the judgement 
of the treating ophthalmologist if there is a suspicion 
of mixed bacterial and FK: Moxifloxacin 0.5% eye- 
drops (Centaur Pharmaceuticals, India).
4. Mydriatic eye- drops for pupil dilation to reduce dis-
comfort from the infection: cyclopentolate 2% eye- 
drops (Aurolab, India), three times a day.
5. Ocular hypotensive eye- drops if the intraocular pres-
sure is elevated >25 mm Hg. This will be at the dis-
cretion of the supervising clinician; usual first line 
treatment is timolol 0.5% eye- drops (Allergan, India).
Ancillary treatment in patients refractory to trial medication
In patients with progressive FK despite 7 days or more 
of trial medication, additional treatment options will be 
considered and offered. After repeating microbiological 
tests to rule out a mixed bacterial infection, deteriorating 
patients are started on topical voriconazole 1% hourly if 
the ulcer is superficial only. For ulcers that are deeper 
than 75% of the corneal thickness, oral ketoconazole 
200 mg two times a day is added (with monitoring of liver 
function). The choice of ancillary treatment is due to local 
availability. If, following 7 days of additional treatment, 
despite these measures there is ongoing progression, 
surgical management such as a TPK can be considered.
Non-pharmacological treatment
It is sometimes necessary to perform surgical procedures 
during the management of corneal infections. In the 
context of the trial these will be performed by the super-
vising consultant ophthalmologist. These can include:
1. Insertion of a bandage contact lens for very small 
perforations.
2. Tissue glue and patch for small perforations.
3. Corneal transplant (TPK) for progressive fungal infec-
tions that are refractory to medical management or 
large perforations.
4. Conjunctival flaps to cover corneas in non- healing 
ulcers.
Outcome measures
Primary outcome measure
The primary outcome will be BSCVA in logMAR units at 
3 months. This will be measured by a trial- certified optom-
etrist, independent of all other aspects of the study and 
masked to allocation. This has been the primary outcome 
of several other trials and will therefore facilitate compar-
ison. Three months is the time at which clinical experi-
ence suggests most corneal ulcers have usually healed. 
BSCVA is chosen as it is easy to measure and is of func-
tional significance. We will measure the BSCVA using 
an LED- backlit, Tumbling- E LogMAR chart (Good- Lite, 
Illinois, USA) under controlled conditions. We will also 
measure vision using Peek Acuity, a validated smartphone 
application, in situations where the patient is unable to 
attend the hospital for follow- up and outcome data is 
only available through a domiciliary visit.29 For patients 
who have counting fingers (CF) vision or less, predefined 
logMAR values will be assigned based on previous clinical 
trials.30 31 Similarly, for patients who undergo a corneal 
transplant (TPK), a predefined visual acuity of 1.9 
logMAR will be given, or last observation carried forward 
(whichever is the better vision), as per previous studies.6
Secondary outcome measures
We will be assessing a number of secondary outcome 
measures that relate to different measures of visual acuity 
such as Peek Acuity; clinical signs of healing such as reduc-
tion of epithelial defect; microbiological culture rates and 
other clinical outcome measures such as scar size or perfo-
ration rate. These secondary outcomes together with their 
analyses are outlined in the Analysis Plan section.
Outcome assessments
Participants will be reassessed at 2 days, 1 week, 2 weeks, 
3 weeks, 2 months and 3 months following enrolment. Addi-
tional examinations, outside the trial protocol schedule may 
be conducted by the supervising clinician as indicated. The 
specific assessments to be carried out at each visit are indi-
cated in table 3. These will be conducted in the same way 
described for the baseline assessment as described (table 2). 
At each follow- up assessment, the participant will be asked 
about adherence to treatment and symptoms, including side 
effects, if still receiving trial treatment. This will be recorded 
in the case record file. To monitor trial medication adher-
ence, the study participants will be asked to bring their eye- 
drop bottles to the 1- week, 2- week and 3- week follow- ups. 
The amount of remaining medication will be measured by 
weighing the bottle and will be compared with the anticipated 
remaining amount provided the drops were being used as 
instructed, resulting in a ratio of actually remaining to what 
is anticipated. Participants will be resupplied with medication 
as needed. The presenting visual acuity will be measured on 
each visit. In addition, the BSCVA will also be measured at the 
3- month follow- up (primary outcome measure). At the final 
3- month follow- up, the three quality of life questionnaires 
will be repeated. On each occasion the eyes will be examined 
using a slit- lamp and the cornea photographed. The IVCM 
will be repeated at 1, 2 and 3 weeks to determine whether 
there is evidence of fungal hyphae resolution with the frag-
mentation of linear elements. At the 1- week follow- up if the 
ulcer has not healed it will be rescraped for repeat culture 
to determine whether the keratitis is now culture positive or 
culture negative. We will give the study participants appoint-
ment cards for the next follow- up and they will be reminded 
about the follow- up a week prior to the date. Public transport 
costs will be paid for participants who are outpatients.
Treatment review
At each follow- up visit, participants will be reviewed by an 
ophthalmic clinician experienced in the management of 
FK. Clinical responses to antifungal therapy tend to be rela-
tively slow (compared with bacterial infections). Prolonged 
topical treatment courses of 4–6 weeks are usually needed. 
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Therefore, a change in therapy is usually not made for at least 
the first week. Other interventions may be indicated such as 
application of glue to corneal perforations, conjunctival flaps 
or TPK (corneal transplant).
Stopping rules
If the study eye develops any serious adverse outcomes, 
the antifungal study medication may be discontinued if it 
is considered to be responsible for the adverse event. The 
patient will then be treated at the discretion of the super-
vising ophthalmologist, without breaking the randomisation 
code. If the medication is stopped, the patient will continue 
with the scheduled follow- up examinations.
Lost to follow-up
Lost to follow- up rates are expected to be low, based on clin-
ical experience. Participants who do not present for their 
follow- up visit will be contacted by telephone. Reasons for the 
lost to follow- up will be identified. Patients will be counselled 
about the importance of attending for ongoing treatment 
and monitoring. If they are unwell or unable to attend the 
hospital for some specific reason the study team will arrange 
to visit them in their home. Reasons for lost to follow- up will 
be recorded and reported.
Data collection, management, confidentiality and access to 
data
Data will be collected using paper clinical record forms. 
These will be stored securely at SCEH and scanned electronic 
copies taken at the end of the day, stored on an encrypted 
drive with encrypted backups made daily both on and off- 
site. These data will be double entered into two separate MS 
Access databases. After double data entry has been completed 
data will be cleaned using EpiData V.3.1 software. Data entry 
is supervised by the local study coordinator on a daily basis, 
with data collection and data entry progress being reviewed 
by the study coordinator and chief investigator at LSHTM on 
a weekly basis. Data protection and confidentiality is main-
tained through restricted access to the database system and 
cupboard where the paper documents are kept. Only autho-
rised users will have access to the locked filing cabinet. The 
database will be password protected, with each data entry staff 
member having their own password. Data exports for further 
analysis will be anonymised.
Data and safety monitoring board
The data and safety monitoring board (DSMB) for this trial 
includes independent experts in bioethics, biostatistics, epide-
miology and ophthalmology appointed by the trial steering 
committee and approved by the national regulatory author-
ities, before the start of the study. The DSMB meets at least 
twice each year and organises teleconferences as needed for 
progress reporting. The study protocol and modifications are 
subject to review and approval by ethics committees in Nepal 
and LSHTM, and by the DSMB. The DSMB will monitor any 
severe or unexpected events and oversees the data collected. 
The DSMB will be responsible for reviewing the results of the 
interim analysis and determining whether or not the trial 
should continue, with or without modifications.
Monitoring for harm
Patients will be monitored at each visit for adverse events or 
reactions. We will follow standardised definitions for adverse 
events, adverse reactions, unexpected adverse reactions, 
serious adverse events or reactions, and suspected unexpected 
serious adverse reaction. These, along with the reporting 
scheme, are given in online supplementary appendix 2.
Biological specimens
The processing and analysis of biological specimens are 
detailed in online supplementary appendix 3.
Sample size considerations
The study is powered to test the hypothesis that CHX is non- 
inferior to NATA in terms of the primary outcome (BSCVA 
at 3 months) at a prespecified non- inferiority margin (Delta) 
of 0.15 logMAR units. It is possible that CHX is non- inferior 
to NATA, given pilot RCT data that showed no statistically 
Table 3 Baseline and follow- up assessment components
Assessment item Baseline Day 2 Day 7 Day 14 Day 21 Day 60 Day 90
History/baseline questionnaire X             
Check treatment adherence   X X X X X X
Check for side effects   X X X X X X
Visual acuity—presenting X X X X X X X
Visual acuity—BSCVA X           X
Contrast sensitivity X           X
Slit- lamp examination X X X X X X X
Cornea photography X X X X X X X
In vivo confocal microscopy X   X X X     
Cornea samples (microbiology/PCR) X   X         
Quality of life tools X           X
BSCVA, best spectacle corrected visual acuity.
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Table 4 Secondary outcome measures that will be investigated as part of the trial, together with analysis details
Secondary outcome 
measure Details
Three- week BSCVA We will analyse the secondary outcome of 3 weeks BSCVA in logMAR in the same manner as the 
primary analysis of the primary outcome described above. The 3 weeks BSCVA will include values 
taken between 18 days and 5 weeks, with the value closest to 3 weeks used.
Presenting VA by Peek We will analyse the presenting VA by Peek Acuity with and without pinhole at 3 months as a secondary 
outcome. This will be of interest if we are unable to get reliable BSCVA measurements at 3 months 
(ie, if patients fail to attend and we need to attend their houses for visual acuity testing). This will be 
performed in the same way as the primary analysis of the primary outcome. We will also perform a 
sensitivity analysis including those lost to follow- up, by using the most recent observation of this 
variable.
Scar/infiltrate size at 
1 week, 3 weeks and 
3 months by slit lamp 
examination
The geometric mean of the two principle axes in mm of the scar or infiltrate at 1 week, 3 weeks and 
3 months will be used as a secondary outcome variable. The slit- lamp scar size will be compared 
at each of these time points between treatment arm in the same manner as described above. This 
will be by linear regression, with treatment arm and baseline infiltrate/scar size as pre- specified 
covariates. This controls for the baseline infiltrate/scar size.
Time to full epithelial 
healing (slit lamp 
examination by 
ophthalmic clinician)
Time of re- epithelialisation will be defined as the midpoint between the last review where an epithelial 
defect (ED) was present and the subsequent review where there was no ED. An area of fluorescein 
staining of less than 0.5 mm will be considered as a resolved ED due to the difficulty in differentiating 
a smaller defect from a small amount of fluorescein pooling observed in a healed defect.
Analysis of time to healing will use Cox proportional hazards regression with treatment group as 
the primary predictor and with predictors of baseline ED size (using the geometric mean in mm as 
outlined above). Survival curves will be plotted using Kaplan- Meier analysis for both treatment arms 
up to the final visit at 3 months. The proportional hazards assumption will be checked by stratifying 
on quartiles of the baseline ED size and if the assumption does not hold, the stratified results will be 
the ones reported. Additionally, treatment failure (defined as persisting epithelial defect greater than 
0.5 mm at the 3 month review) will be compared between treatment groups using Fisher’s exact test.
Rate of healing We will assess how quickly the area of ulceration reduces over time. The rate will be calculated 
between the 1- week, 3- week and 3- month review by taking the difference in ED size between the 
two time points, in mm, and diving by the number of days to give a rate of mm/day. Analysis will be 
performed using Cox regression.
Microbiological cure Patients who have a persisting corneal ulcer (as defined by the presence of an ED) at day 7 will 
undergo a repeat corneal scrape and microbiological investigations. Microbiological cure at 7 days will 
be defined as the absence of any micro- organisms as no significant growth on culture. The number of 
patients with microbiological cure at day 7 will be compared between the two treatment arms using 
logistic regression with treatment group and organism (Aspergillus spp, Fusarium spp, or other) as 
covariates.
Ulcer depth at 1 week 
and 3 weeks (slit 
lamp examination by 
ophthalmic clinician)
The depth of ulcer in terms of percentage of healthy cornea will be compared at 1 week and 3 weeks 
between treatment arms, adjusting for baseline depth in the same manner with analysis performed by 
linear regression
Hypopyon height at 
1 and 3 weeks, (slit 
lamp examination by 
ophthalmic clinician)
The hypopyon height in mm will be compared at 1 week and 3 weeks between treatment arms, 
adjusting for baseline hypopyon height in the same manner with analysis performed in the same way 
(linear regression)
Perforation and/or TPK 
and/or conjunctival 
advancement by 
3 months (slit lamp 
examination by 
ophthalmic clinician)
The number of patients who undergo perforation and/or require TPK and/or have undergone 
conjunctival advancement by 3 months will be reported using CIs and descriptive statistics. The 
study is not powered to detect a difference in perforation rate or TPK between treatment groups; not 
reporting a significant difference may be wrongly interpreted as there being no difference between 
groups. We will therefore perform an exploratory analysis to compare TPK or perforation rates 
between treatment groups. This will be by logistic regression to compute an OR by arm.
Loss of eye The number of patients who have their eye surgically removed (evisceration or enucleation) during 
the 3 months follow- up period will be reported using CIs and descriptive statistics in the same way as 
for TPK/perforation rate above, along with exploratory analysis using logistic regression to find risk 
factors for eye loss and OR for this by arm.
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significant difference between CHX and NATA, with a 
Cochrane review finding a non- significant trend favouring 
CHX over NATA.10 18 19 Despite this trend favouring CHX, we 
have chosen to carry out a non- inferiority trial rather than a 
superiority trial as this is a more clinically pragmatic approach. 
It would be counterproductive to conduct a superiority trial 
and find no statistically significant difference between the two 
treatments leading clinicians to potentially disregard CHX as 
a treatment, when in fact it may be ‘non- inferior’ to NATA, 
and be the only available or most cost- effective treatment.
The choice of delta: This clinically meaningful difference 
of 0.15 logMAR was chosen as a difference of 0.15 logMAR 
corresponds to approximately 1.5 lines on a Snellen chart; 
any difference greater than this is clinically significant, as a 
difference of less than 0.15 log MAR could potentially be 
accounted for by testing/retesting error.29 Furthermore, 
it was used in the MUTT1 trial, providing methodological 
consistency between studies.6 In addition, previous studies 
have suggested treated ulcers improve at a mean of four 
Snellen lines from baseline.
Sample size was calculated for 90% power and adjusted 
final alpha of 0.0492, taking account of a single interim 
analysis using O’Brien- Fleming approach to maintain type-1 
error rate of 5%. A sample size of 452 is required to detect a 
non- inferiority margin of 0.15- logMAR in BSCVA 3 months 
after enrolment between arms, assuming 0.5 SD for 3 months 
BSCVA and 15% drop- out. However, given approximately 
10% of infections are mixed and these will be excluded 
from the primary analysis, 500 patients will be recruited. 
This sample size provides 90% power to detect superiority in 
BSCVA at 3 months if there is ≥0.17 LogMAR units difference 
as a secondary analysis.
Analysis plan
The analysis will be by intention to treat (ITT). All patient 
data will be analysed according to their randomisation 
Secondary outcome 
measure Details
Ocular adverse effects, 
slit lamp examination 
by ophthalmic clinician
The proportion of patients with one or more adverse events will be compared using Fisher’s exact 
test. Additional analysis to compare the rate of adverse events during the 3 months follow- up will be 
by Poisson regression as this can take into account multiple instances within one participant.
QoL assessed using: 
EQ- 5D, WHO/PBD- 
VF20, WHOQOL- BREF
QoL can be assessed quantitatively using different tools depending on what is of interest. For 
example, disease- related QoL can be assessed (eg, vision related QoL, VRQoL) or more general 
health- related issues irrespective of the disease can be investigated (health- related QoL, HRQoL).40
We will use the WHO/PBD- VF20 (WHO/ Prevention of Blindness and Deafness—Visual Functioning 
20- item questionnaire) VRQoL tool. This tool measures the impact of visual impairment in the person’s 
life including mental well- being, dependency and social functioning. These have been used in a 
number of other visual related studies to show a difference in QoL.36 37
For HRQoL, we will use the EQ- 5D questionnaire, EQ- Visual Analogue Scale and the WHOQOL- BREF. 
The EQ- 5D is a standardised tool to measure health outcomes.38 The WHOQOL- BREF has good 
applicability in (LMIC as it was developed simultaneously from concept across 18 countries in Africa, 
Asia and Latin America. It measures four domains of health: Physical Health, Psychological Health, 
Social Relationships, and Environment. Details of this scoring are given in table 2.39
Analysis will be by comparing the scores obtained for each QoL assessment for the two treatment 
arms to estimate the effect of CHX and NATA on patients’ QoL. This will be similar to that performed 
by Habtamu et al.40 Comparisons between the two medication groups will be adjusted for the 
matching variables: age and sex. The VRQoL analysis was also adjusted for socio- economic status 
and the HRQoL analysis adjusted for both socioeconomic status and presence of health problems 
during the previous 4 weeks, as these factors may confound the association between fungal keratitis 
and QoL. Logistic, linear and ordinal logistic regression methods will be used for binary, continuous 
and ordered categorical outcome variable analysis, respectively. Linear regression models and the t- 
test were employed to compare significant differences in QoL scores and to generate mean and mean 
differences between the two treatment arms in each QoL subscale and domain, respectively.
Cost- effectiveness 
analysis, using EQ- 5D 
data from 3 months 
and direct cost data
Direct cost data will be collected at the 3 months follow- up. Economic costs to the patient can also be 
calculated from the EQ- 5D questionnaire, which will be asked at baseline and at the 3 months follow- 
up. Mean direct costs incurred by patients will be compared between interventional arms using the 
t- test for significance. The difference from the baseline EQ- 5D and the 3 months EQ- 5D mean scores 
will also be compared in a similar fashion.
Drug adherence The rate of drug adherence will be compared between the two treatment groups using descriptive 
statistics.
BSCVA, best spectacle corrected visual acuity; EQ- 5D, EuroQol-5 dimensions; LMIC, low- income and middle- income countries; QoL, quality 
of life; TPK, therapeutic penetrating keratoplasty.
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Table 5 Registration data and protocol summary
Data category Information
Primary registry and trial 
identifying no
ISRCTN Registry; ISRCTN14332621
Date of registration in 
primary registry
15 May 2019
Secondary identifying 
numbers
  
Source(s) of monetary or 
material support
Wellcome Trust
Primary sponsor London School of Hygiene and Tropical Medicine
Secondary sponsor(s)   
Contact for queries Jeremy Hoffman FRCOphth (Jeremy.hoffman@lshtm.ac.uk)
Title Chlorhexidine 0.2% vs Natamycin 5% for the treatment of fungal corneal infections
Countries of recruitment Nepal
Health condition(s) or 
problem(s) studied
Fungal keratitis
Intervention(s) Participants will be randomised to either topical chlorhexidine 0.2% or topical natamycin 5%
Key eligibility criteria 1. Acute MK characterised by:
 ► Corneal epithelial ulceration >1 mm diameter
 ► Corneal stromal infiltrate
 ► Acute inflammation: for example, conjunctival injection, anterior chamber inflammatory cells, 
hypopyon
2. Filamentous fungal hyphae visualised on smear microscopy and/or in vivo confocal microscopy
3. Agree to be randomised to either treatment arm and able to give informed consent
4. Agree to be followed up at 2 days, 1 week, 2 weeks, 3 weeks, 2 months and 3 months
5. Adults (18 years and older)
Study type Randomised controlled trial
Date of first enrolment 1 June 2019
Target sample size 500
Recruitment status Recruiting
Primary outcome(s) Best Spectacle Corrected Visual Acuity at 3 months by a trial certified optometrist
Key secondary 
outcomes
1. Time to full epithelial healing (slit lamp examination by ophthalmic clinician)
2. Pin- hole visual acuity in logMAR at 3 months, trial- certified optometrist
3. Scar/infiltrate size at 1 week, 3 weeks and 3 months (slit- lamp examination by ophthalmic clinician)
4. Ulcer depth at 1 week and 3 weeks (slit- lamp examination by ophthalmic clinician).
5. Hypopyon height at 1 and 3 weeks, (slit- lamp examination by ophthalmic clinician).
6. Perforation and/or TPK by 3 months (slit- lamp examination by ophthalmic clinician).
7. Positive culture rate at 1 week
8. Ocular adverse effects at each follow- up visit (day 2, day 7, day 14, 3 weeks, 2 months, 3 months), 
slit- lamp examination by ophthalmic clinician
9. Quality of life (QoL) assessed using: EQ- 5D, WHO/PBD- VF20, WHOQOL- BREF (comparison 
between baseline and QoL measures at 3 months)
10. Cost- effectiveness analysis, using EQ- 5D data from 3 months and direct cost data
11. Drug adherence at each follow- up visit (day 2, day 7, day 14, 3 weeks, 2 months, 3 months) while 
the patient is using study medications
EQ- 5D, EuroQol-5 Dimension; LMIC, low- income and middle- income countries; MK, microbial keratitis; TPK, therapeutic penetrating 
keratoplasty.
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allocation irrespective of whether or not the patient 
received or adhered to the allocated treatment. Consol-
idated Standards of Reporting Trials guidelines for 
analysing/reporting non- inferiority RCTs will be followed. 
A flow chart showing cases assessed, recruited and 
followed up by arm will be prepared.32 Baseline character-
istics will be summarised by arm. The Standard Protocol 
Items: Recommendations for Interventional Trials check-
list is given in online supplementary appendix 4.
Primary outcome analysis: unadjusted analysis
The primary analysis will be conducted using all available 
data, missing data due to lost to follow- up will be excluded. 
The primary analysis of the primary outcome (BSCVA at 
3 months) will be by linear regression, with treatment 
arm and baseline BSCVA as prespecified covariates. This 
controls for the baseline BSCVA. The treatment group 
is the primary predictor. Primary analysis will exclude 
mixed fungal and bacterial infection (isolated in the base-
line sample).
We will use our alpha of 0.0492 to test the null hypoth-
eses at 0.0492 significance. The null hypothesis for non- 
inferiority is that the mean BSCVA at 3 months for CHX 
is greater than or equal to 0.15 logMAR worse than the 
BSCVA when natamycin is used. Significance will be 
assessed using a two- tailed test at 0.0492 level for assessing 
non- inferiority. CHX will be non- inferior if the upper one- 
sided 95% confidence level for this regression coefficient 
(ie, the effect of CHX controlling for baseline BSCVA) 
exceeds 0.15 logMAR.
Primary outcome analysis: adjusted analysis
In the event that there is a baseline imbalance between 
the treatment groups in a baseline covariate due to 
chance, we will perform an adjusted (sensitivity) analysis 
(see below). This is particularly important if CHX has a 
better outcome than NATA, as the adjusted treatment 
effects may account for this observed imbalance while the 
unadjusted analyses may not. Sensitivity analyses will allow 
us to show that any observed positive treatment effect is 
not solely explained by imbalances at baseline in any of 
the covariates.
Secondary analyses of the primary outcome
Per-protocol analysis
Repeat analysis of the primary outcome will be done as 
per the protocol, based on what the participants actu-
ally took. The per- protocol population will include all 
the individuals included in the primary ITT analysis, 
excluding individuals who showed poor compliance with 
the medications (defined as taking less than 50% through 
self- reporting or bottle weighing, whichever is the lower); 
individuals where there have been major protocol devia-
tions; and non- fungal or mixed corneal infections (should 
these patients happened to have been randomised). All 
analyses that are performed as ITT will be repeated as per 
protocol and labelled as such.
Mixed infections
Secondary analysis of the primary outcome (by ITT) will 
include mixed infections and will be carried out in the 
same way as in primary analysis of the primary outcome 
above.
Sensitivity analyses
For the primary analysis those individuals with missing 
outcome data (ie, lost to follow- up) will be excluded. 
Sensitivity analyses will be performed by imputing a range 
of scenarios to demonstrate a range of potential results, 
where there is missing outcome data. In the case of 
substantial missing data in the trial, the primary analysis 
will be carried out as previously stated excluding missing 
observations. This, however, assumes data are missing 
completely at random. As a sensitivity analysis, we will 
then apply a multiple imputation approach to the missing 
data, if we consider the data are randomly missing condi-
tional on other observed covariates.
In the case that there is a systematic (ie, non- random) 
reason for a difference in the follow- up rates between the 
two groups, we will explore models in which these missing 
outcome data are assumed to be non- random, that is, 
dependent on the outcome being regressed, BSCVA or 
treatment group.
We will also perform sensitivity analyses on patients 
whose vision is CF or worse, those patients who have 
undergone a TPK or those with corneal perforation, to 
see if there is any change in the effect size or conclusions 
drawn.
Analysis of other potential determinants for success
Logistic regression random- effects models will be used 
to analyse potential factors that may be associated with 
a poor primary outcome, BSCVA at 3 months, defined as 
>1.0 logMAR. Individual baseline characteristics will be 
used separately as an exposure variable with BSCVA at 3 
months as the outcome, with the model adjusted for trial 
arm. A multivariate model will be built using parameters 
with a p<0.2 in the log likelihood ratio test. Variables will 
be removed one by one, by omitting the variable with the 
largest p value each time, until all predictors in the model 
have a p<0.05.
Secondary outcome analysis
The secondary outcomes outlined above and detailed in 
table 4 will be analysed by arm. Additional adjustment 
for factors imbalanced between arms at baseline will be 
introduced as appropriate. Continuous outcomes will 
be analysed using linear regression. Binary and ordinal 
outcomes will analysed using logistic regression. Details 
of these are given in table 4.
Interim analysis
An interim analysis will be conducted for the DSMB by 
an independent statistician after 1/3 of patients recruited 
have completed follow- up.
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Patient and public involvement
Mixed methods descriptive cross- sectional studies with 
semistructured interviews and focus group discussions 
with patients and eye health providers were carried out 
in Sagarmatha zone, Eastern Nepal at various points in 
2018.33 These conversations highlighted the delayed 
presentation often seen with FK combined with the often 
prohibitively high costs of treatment. Furthermore, treat-
ment is not always felt to be effective. Eye health workers 
were keen to receive further training and highlighted the 
need for greater government support in the provision of 
eye care services in the community.
ETHICS AND DISSEMINATION
Ethics committee and regulatory review and approval has 
been obtained from the Nepal Health Research Council 
(NHRC) Ethics Committee, Kathmandu, Nepal; the 
Department of Drug Administration (DDA), Kathmandu, 
Nepal; and the London School of Hygiene and Tropical 
Medicine Ethics Committee, UK. The trial is registered 
with the ISRCTN clinical trials registry. Protocol modifi-
cations are submitted to the relevant parties for review 
and/or approval. Table 5 summarises the study protocol 
and trial registration information. At the end of the study 
period, patients who still require treatment or follow- up 
will continue to be treated at SCEH as per routine clin-
ical practice. The trial sponsor is the LSHTM. The results 
of this trial will be presented at local and international 
meetings and submitted to peer- reviewed journals for 
publication.
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